20 news items
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY
IMAB
5 Jun 24
. Collaboration builds on promising safety and efficacy data from the givastomig monotherapy study reported at the European Society of Medical Oncology
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
-breaking data to be presented at the 2024 American Society of Clinical Oncology (ASCO®) Annual
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
BMY
3 Jun 24
in relapsed or refractory follicular lymphoma (FL).
The data, presented during the 2024 American Society
Bristol Myers Squibb Reveals Opdivo Results for Lung Cancer at ASCO 2024
BMY
3 Jun 24
and advanced non-small cell lung cancer (NSCLC). Data are being presented at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting from May 31 to June 4, 2024, in Chicago, IL.
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
cancer (NSCLC). Data are being presented at the 2024 American Society of Clinical Oncology (ASCO®
wd115ltxjja4
BMY
3 Jun 24
in progression-free survival with KRAZATI compared to standard of care chemotherapy
Late-breaking data featured in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
n0oc0 67i2gdg8
BMY
1 Jun 24
at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
d69 2w4o69whmxf4yk9grg6pr8vqfzeh5rfayrscoticm
AMGN
BMY
VSTM
24 May 24
pancreatic cancer.
The initial interim results will be presented at the upcoming American Society of Clinical Oncology Annual Meeting
g8egytxrke eck6fnf5pfo18b
BMY
23 May 24
) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology
jr91q4jpbrhqz22d61mj8n4aimhli2ghix5i9u4t3jq
BMY
21 May 24
, but society often tells them that their diagnosis means they have to put their goals aside," said Jasmine Greenamyer, Vice President of Patient
cslb26034bu76 iqx4
BMY
CATX
LNTH
15 May 24
was informed by the investigator that updated results from 12 patients have been accepted for presentation at the Society of Nuclear Medicine
ry91r37nvw8ti8dc8v0em18 5k3jyhl6t8izpz
BMY
26 Apr 24
Society
oakkdn88sczrjv 775sjdroutwo1of2g4z
ABBV
ATNM
AZN
19 Apr 24
Actinium's Phase 3 SIERRA trial results, recently unveiled at the 50th Annual European Bone Marrow Transplant Society Meeting
zph7 3fakbpcxz4fx
ATNM
AZN
BMY
18 Apr 24
of the European Bone Marrow Transplant Society (EBMT) being held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy conditioning
44z 1xqv4uiy1y3k9al4t8yemah8e6rmn2e9scpuxpqz75j9
ATNM
AZN
BMY
17 Apr 24
) access. These pivotal findings will be featured at the 50th Annual European Bone Marrow Transplant Society (EBMT) meeting in Glasgow, Scotland
1sj7pmsorws91n1kl8afxrzfwy01hlxudtdfoo3a
BMY
6 Apr 24
) in Schizophrenia" (Poster F264) at the Annual Congress of the Schizophrenia International Research Society (SIRS) being held April 3-7, 2024, in Florence
mb3u1m3sfv60aue9fuwgc4ehc4855t9
BMY
6 Apr 24
Studies EMERGENT-4 and EMERGENT-5" at the Annual Congress of the Schizophrenia International Research Society (SIRS) being held April 3-7, 2024
6bmgx1q1gnq1ubifcls42icmze2410t4df3xso4dsn6giqoz25xs4zkap23o
BMY
CATX
LNTH
28 Mar 24
that were deemed unrelated to [212Pb]VMT-α-NET treatment.Further data readout has been submitted to Society of Nuclear
h2hyhaygp0kycseyxvma4dx mg
BMY
TSVT
15 Mar 24
Society of Hematology (ASH) Annual Meeting and Exposition in December
zf47uqd2yumff5hyi3jibnmme3osvvuw8ftrrbmeqoj2fi1
BMY
14 Mar 24
officer of CLL Society. "The approval of Breyanzi as the first CAR T cell therapy available for relapsed
- Prev
- 1
- Next